FTC Med Spa Enforcement Patterns 2024-2026: The Specific Claim Categories Drawing Attention

Med spas are one of the fastest-growing healthcare practice categories and one of the highest-volume recipients of FTC enforcement action. 2024-2026 has seen a sustained pattern of FTC attention to specific marketing categories that most practices are still producing. This post covers the specific patterns the agency is pursuing and what practices should adjust.

Pattern 1: Typical-experience disclosure gaps

Before/after imagery and patient testimonials without proper typical-experience disclosure are the single most-common FTC enforcement pattern in med spas. “Results may vary” is not sufficient disclosure under the 2023 Endorsement Guides update - typical actual outcomes must be disclosed.

What the agency is finding: most med spa before/after content pairs peak-outcome imagery with minimal disclosure, creating the impression that peak outcomes are typical. This is the specific pattern the FTC has pursued in multiple recent actions.

Pattern 2: Material-connection gaps in influencer content

Influencer partnerships without FTC-compliant disclosure of paid relationships are a persistent pattern. The 2023 Endorsement Guides update tightened the clear-and-conspicuous standard, and enforcement has followed.

Specific issues: #ad buried in long caption blocks, disclosure in bio link rather than in the post, disclosure in platform-specific paid partnership tools that don’t make the paid status visually prominent, and free-treatment relationships treated as non-paid.

Pattern 3: Aggressive package pricing marketing

Package pricing advertised at introductory rates without adequate disclosure of actual-total pricing (including add-ons, anesthesia, follow-up, recommended treatment series) has been a growing state AG and FTC focus.

The pattern: “$X for CoolSculpting cycle” where the actual treatment plan involves multiple cycles at non-promotional rates, or “$Y for lip filler” where the typical treatment requires more filler than the promotional amount.

Pattern 4: FDA-approved vs FDA-cleared misuse

Device marketing conflating “FDA-approved” with “FDA-cleared” is one of the most consistently-cited patterns across med spa enforcement. Most aesthetic devices are 510(k) cleared; using “FDA-approved” for these is factually wrong.

Pattern 5: Off-label indication promotion

Marketing neuromodulators or fillers for specific off-label indications - jawline slimming, non-surgical rhinoplasty, specific body-contouring applications - is a sustained enforcement pattern. Clinical off-label use may be appropriate; public marketing of off-label indications is not.

Pattern 6: Guarantee and superlative claims

“Guaranteed results,” “best in [city],” “most experienced” without substantiation are common in med spa marketing and consistently cited in enforcement.

Pattern 7: Nurse injector independence language

Coordinated enforcement between state medical boards and FTC on marketing that implies nurse-injector independence when supervision is required. This is a state-medical-board-plus- FTC pattern that creates simultaneous exposure.

Pattern 8: Safety absolutes

“No side effects,” “completely safe,” “painless” - absolute safety claims in aesthetic marketing. These conflict with documented side effect profiles of every injectable, laser, and RF device.

Pattern 9: Celebrity and influencer stock content

Using celebrity imagery or stock content to imply celebrity endorsement when none exists. The 2023 Endorsement Guides specifically address this pattern as deceptive.

Pattern 10: AI-generated testimonials and imagery

An emerging pattern: AI-generated patient testimonials or AI-modified before/after imagery presented as real. The 2023 Guides explicitly flag this as deceptive, and enforcement is expected to develop in 2026.

What med spa practices should adjust

1. Audit every before/after for typical-experience framing.Replace “results may vary” with actual typical-outcome language.
2. Review every influencer partnership for disclosure adequacy. Clear-and-conspicuous in the post itself, not in bio or description.
3. Restructure package pricing marketing.Clear disclosure of what’s included and typical total-treatment cost.
4. Correct FDA-approved vs FDA-cleared language.One afternoon of site audit closes this specific pattern.
5. Review off-label indication marketing.Generic treatment-category marketing vs specific off-label-indication marketing.
6. Remove guarantee language. Outcome guarantees in aesthetic practice create both FTC and private-action exposure.
7. Add supervision disclosure where required.State-specific supervision language for nurse injectors and non-physician providers.
8. Replace safety absolutes.“Most patients tolerate well” with specific common side effects.
9. Verify all imagery is real patients. No stock content presented as patients, no AI-generated patients.
10. Document the compliance program.Pre-publish review, trained staff, audit schedule.

Outlook for 2026

Expect med spa enforcement to continue and expand. The category’s growth outpaces its compliance maturation in most markets. The FTC has signaled continued attention to aesthetic practice marketing specifically, and state AGs increasingly coordinate on med spa cases.

Practices that invested in compliance infrastructure in 2024 and 2025 enter 2026 in a defensible posture. Practices that treated compliance as optional are increasingly outliers in a tightening regulatory environment.